Search clinical trials for: Mylan's insulin glargine

Total 2856 results

Sanofi

Completed

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) (LixilanOne CAN)

Type 2 Diabetes Mellitus

Canada
Sanofi

Completed

Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. (DINAMO)

Diabetes Mellitus, Type 2

Brazil
Sanofi

Completed

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (GEMELLI X)

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes (EUROMIX)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Hungary, Slovenia, Germany, Czech Republic, Poland, Slovakia
Sanofi

Terminated

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (TRENT)

Type 2 Diabetes Mellitus | Renal Impairment

United States, Czechia, Hungary, Poland, Serbia
Baylor College of Medicine

Completed

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients (GIH)

Hyperglycemia | Diabetes Mellitus

United States
Sanofi

Completed

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Diabetes Mellitus

United States
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States, Chile, Czech Republic, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden
Washington University School of Medicine

Completed

Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients

Hyperglycemia | Lymphoma | Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo (AUTOMATIX)

Type 2 Diabetes Mellitus

Germany, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Diabetes Mellitus, Type 2
Sanofi

Active, not recruiting

Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs (SAFEGUARD)

Type 2 Diabetes Mellitus

India
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
Xijing Hospital

Completed

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
University of Colorado, Denver
Sanofi

Completed

Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

Diabetes

United States
Joslin Diabetes Center
Sanofi

Completed

Simplified Insulin Protocol Using Lantus in Elderly (SIMPLE)

Diabetes

United States
Diabetes Care Center
Novo Nordisk A/S

Completed

A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia
University of Sao Paulo General Hospital

Completed

Glargine Versus NPH in Patients With Chronic Kidney Disease

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Brazil
Novo Nordisk A/S

Completed

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Poland, Slovakia, Canada, Slovenia, Greece, Czechia
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM (LixiLan-O)

Type 2 Diabetes

Australia, Denmark, South Africa, Spain, Belgium, Russian Federation, Canada, Estonia, Hungary, Latvia, Mexico, United States, Chile, Czech Republic, France, Germany, Italy, Lithuania, Poland, Romania, Sweden, Ukraine, United Kingdom
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Sanofi

Completed

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (B to B)

Diabetes Mellitus, Type 2

Korea, Republic of
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Completed

Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial) (RESET-IT)

Type 2 Diabetes

Canada
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-L)

Type 2 Diabetes

United States, Australia, Canada, Chile, Czech Republic, Denmark, Estonia, Hungary, Lithuania, Mexico, Netherlands, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine
Yale University

Completed

Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs (PK/PD)

Diabetes Mellitus, Type I
Brigham and Women's Hospital
Sanofi

Terminated

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Federico II University

Completed

One Year Glargine Treatment in CFRD Children and Adolescents

Glucose Metabolism Disorders | Cystic Fibrosis

Italy
Halozyme Therapeutics

Completed

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Sanofi

Completed

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)

Diabetes

Peru, Ukraine, Colombia, Egypt, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates
Gan and Lee Pharmaceuticals, USA

Completed

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (GLITTER 1)

Diabetes Mellitus, Type 1

Spain, United States, Germany, Czechia, Hungary, Poland
Emory University

Completed

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients (CABG-D/C)

Poor Glycemic Control

United States
Sanofi

Completed

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

Type 1 Diabetes Mellitus

Germany
LMC Diabetes & Endocrinology Ltd.
Sanofi

Completed

Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration (INNOVATE)

Type 2 Diabetes Mellitus

Canada
Population Health Research Institute

Completed

REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) (RECREATE Pilot)

Hyperglycemia | Myocardial Infarction | Cardiovascular Diseases

Argentina, Canada, India
Handok Inc.

Completed

Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Korea, Republic of
Medical University of South Carolina

Completed

IV Insulin Protocol in Diabetes and Renal Transplantation

Hyperglycemia | Diabetes | Kidney Transplantation

United States
Chattanooga-Hamilton County Hospital Authority

Terminated

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

Diabetes Mellitus, Type 1 | Diabetic Ketoacidosis

United States
AstraZeneca
Eli Lilly and Company

Completed

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Type 2 Diabetes Mellitus

Italy, Poland, Hungary, Mexico, Greece, Australia
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Slovakia, Spain, France, Hungary, Mexico, Russian Federation, Turkey, Czechia, Greece, Argentina
Sanofi

Completed

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin (ARTEMIS-DM)

Type 2 Diabetes Mellitus

Argentina, Colombia, Egypt, Hong Kong, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Turkey
Gan and Lee Pharmaceuticals, USA

Completed

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (GLITTER 2)

Diabetes Mellitus, Type 2

United States
Sandra Sobel

Completed

Remission Through Early Monitored Insulin Therapy - Duration Month (REMIT-DM)

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

DOMME Dose Optimization Multicentric Mexican Evaluation (DOMME)

Diabetes Mellitus, Type 2

Mexico
The University of Texas Health Science Center,...

Completed

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis (GT-COG)

Diabetic Ketoacidosis

United States
Vanderbilt University Medical Center

Completed

Use of Insulin Glargine to Treat Diabetic Ketoacidosis

Diabetic Ketoacidosis

United States
Eli Lilly and Company

Completed

A Study in Patients With Type 2 Diabetes Mellitus (IMAGINE 2)

Diabetes Mellitus, Type 2

United States, Brazil, Germany, Israel, Italy, United Kingdom, Australia, Hungary, Puerto Rico, Romania, Russian Federation, Spain, Poland, Canada, Greece, Turkey, Mexico, New Zealand, South Africa, Argentina, Finland, Lithuania, Sl...
Sanofi

Completed

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (Soli-CGM)

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment (LANCELOT)

Diabetes Mellitus, Type 2

Brazil, Thailand, Slovakia, Poland, Netherlands, Kuwait, Mexico, Korea, Republic of, Czech Republic, Egypt, France, Italy, Romania, Russian Federation, Sweden, Switzerland, United Arab Emirates

3

Subscribe